Kidney Compass: The PARASOL Initiative, with Laura Mariani, MD, MS, and Daniel Gale, PhD, MB BChir
Key Takeaways
- Kidney Compass explores nephrology clinical trials, focusing on the PARASOL Initiative and FSGS.
- The PARASOL Initiative investigates short-term biomarker changes as alternative endpoints for drug approval in FSGS.
This 4-part episode focuses on the PARASOL Initiative and the landscape of focal segmental glomerulosclerosis treatment.
Welcome to
Produced by
After a 3-episode run at the
An international collaboration, the Proteinuria and GFR as Clinical Trial Endpoints in FSGS (PARASOL) Initiative was launched to investigate a link between short-term changes in biomarkers, like proteinuria and GFR, and long-term outcomes to support alternative endpoints for drug approval. Mariani co-chairs the project, which is led by the Michigan Kidney Translational Medicine Center and sponsored by NephCure, the International Society of Glomerular Disease, the Kidney Health Initiative, and the National Kidney Foundation.
For ease of viewing, we've divided this episode, which contains more than an hour of insights into the PARASOL Initiative and FSGS, into 4 sections and highlighted them above.
The entire, uninterrupted episode is available in an audio-only format on
Related Content
